Albireo Pharma, Inc.
ALBO · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 388.4% | -13.8% | -24.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 96.7% | 100% | 77.1% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -48.9% | -1,156.5% | -594.6% | -297.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -373% | -1,432.3% | -744.1% | -361.9% |
| EPS Diluted | -7.87 | -7.45 | -5.77 | -3.94 |
| % Growth | -5.6% | -29.1% | -46.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |